ANPCY News and Press, Angle Plc Surrey ADR From 03/25/22

PARSORTIX SHOWS POTENTIAL FOR IDENTIFYING THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER Parsortix system harvests intact CTCs for whole genome sequencing identifying multiple actionable targets Both tumour and CTC samples after pre-surgical chemotherapy show a...

ANGLE's US clinical laboratory issued Certificate of Registration, a key step to achieving CLIA accreditation GUILDFORD, UK / ACCESSWIRE / March 15, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, provides an update on the accreditation of its clinical la...

PEER-REVIEWED PUBLICATION HIGHLIGHTS POTENTIAL FOR PARSORTIX SYSTEM IN IMMUNOTHERAPY TREATMENT SELECTION Parsortix isolation of CTCs highlights relationship between PD-L1 expression and epithelial to mesenchymal transition (EMT) CTCs in the process of epithelial mesenchymal transit...

BREAKTHROUGH STUDY DEMONSTRATES FOR THE FIRST TIME CONCORDANCE OF PARSORTIX LIQUID BIOPSY BLOOD TEST WITH INVASIVE TISSUE BIOPSY OF THE METASTATIC SITE Study explores key unmet medical need for metastatic breast cancer as over 50% of patients fail to receive successful tissue biopsies o...

First submissions made in relation to accreditation of ANGLE clinical laboratories Ovarian cancer study sample analysis slower than planned GUILDFORD, SURREY / ACCESSWIRE / January 13, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, provides an updat...

EPIGENETIC ALTERATIONS IN GENES FROM LIQUID BIOPSIES PROVIDE INSIGHT INTO DRUG RESISTANCE IN NON-SMALL LUNG CANCER PATIENTS Longitudinal analysis of paired samples of CTCs and ctDNA shows important differences in epigenetic biomarkers at disease progression Study supports analysis ...

ANGLE'S PARSORTIX SYSTEM KEY TO STUDY DEMONSTRATING RNA ANALYSIS OF CTCs AS A PROGNOSTIC TOOL IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS Research published by world-class cancer research centre highlights critical advantages of the Parsortix system Multi-marker transcriptomic a...

Angle (OTCQX:ANPCY) issues 50,000 new ordinary shares of £0.10 each in the company. The new ordinary shares will rank pari passu with the existing ordinary shares in the company. It is expected that admission will become effective, and trading will commence at 8.00 a.m. on 2 De...

PARTICIPATION AT JEFFERIES LONDON HEALTHCARE CONFERENCE GUILDFORD, UK / ACCESSWIRE / November 12, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that Andrew Newland, Chief Executive Officer, and Ian Griffiths, Chief Financial Office...

Study in metastatic prostate cancer presented at NCRI Festival demonstrates longitudinal analysis of CTCs harvested using the Parsortix system is predictive of treatment response KLK2 gene expression on CTCs found to be a more effective biomarker for assessing likelihood of cancer progr...